

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2012**

**PART I**

(Rs. in Lacs)

Sr. No.	Particulars	Quarter ended 30/06/2012	Previous Quarter ended 31/03/2012	Corresponding Quarter ended 30/06/2011	Six months ended 30/06/2012	Corresponding Six months ended 30/06/2011	Twelve Months ended 31/12/2011
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
	a) Net Sales/Income from Operations	22,567.82	20,752.35	44,605.17	43,320.17	88,433.32	166,195.39
	b) Other Operating Income	213.45	228.90	193.71	442.35	520.06	930.78
	<b>c) Total Income from Operations</b>	<b>22,781.27</b>	<b>20,981.25</b>	<b>44,798.88</b>	<b>43,762.52</b>	<b>88,953.38</b>	<b>167,126.17</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	11,920.90	18,227.17	22,767.86	30,148.07	42,639.34	102,799.60
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4,249.10	(2,930.64)	(413.90)	1,318.46	(5,101.92)	(14,836.69)
	d) Employee benefits expense	1,342.76	1,357.82	1,217.04	2,700.58	2,395.96	5,056.56
	e) Depreciation and amortization expense	6,321.16	6,362.44	6,995.15	12,683.60	13,031.56	25,709.95
	f) Other Expenses	1,321.71	1,232.73	2,218.52	2,554.44	9,867.31	9,435.24
	<b>g) Total Expenses</b>	<b>25,155.63</b>	<b>24,249.52</b>	<b>32,784.67</b>	<b>49,405.15</b>	<b>62,832.25</b>	<b>128,164.66</b>
3	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(2,374.36)</b>	<b>(3,268.27)</b>	<b>12,014.21</b>	<b>(5,642.63)</b>	<b>26,121.13</b>	<b>38,961.51</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(2,374.36)</b>	<b>(3,268.27)</b>	<b>12,014.21</b>	<b>(5,642.63)</b>	<b>26,121.13</b>	<b>38,961.51</b>
6	Finance Costs	10,932.67	10,371.23	6,273.94	21,303.90	12,591.58	27,043.08
7	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(13,307.03)</b>	<b>(13,639.50)</b>	<b>5,740.27</b>	<b>(26,946.53)</b>	<b>13,529.55</b>	<b>11,918.43</b>
8	Tax expense						
	a) Current	0.00	0.00	935.67	0.00	2,495.67	570.02
	b) Deferred	(4,317.00)	(4,425.00)	608.18	(8,742.00)	1,708.18	300.01
	c) Total	(4,317.00)	(4,425.00)	1,543.85	(8,742.00)	4,203.85	870.03
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(8,990.03)</b>	<b>(9,214.50)</b>	<b>4,196.42</b>	<b>(18,204.53)</b>	<b>9,325.70</b>	<b>11,048.40</b>
10	Extraordinary Items	0.00	0.00	(1,061.94)	0.00	(1,061.94)	(9,135.22)
11	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(8,990.03)</b>	<b>(9,214.50)</b>	<b>3,134.48</b>	<b>(18,204.53)</b>	<b>8,263.76</b>	<b>1,913.18</b>
12	Prior year adjustment	0.00	0.00	0.00	0.00	0.00	81.69
13	<b>Profit available for appropriation</b>	<b>(8,990.03)</b>	<b>(9,214.50)</b>	<b>3,134.48</b>	<b>(18,204.53)</b>	<b>8,263.76</b>	<b>1,994.87</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						246,410.14
16.i	Earnings Per Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(3.36)	(3.44)	1.61	(6.80)	3.57	4.12
	b) Diluted	(2.97)	(3.05)	1.43	(6.02)	3.16	3.65
16.ii	Earnings Per Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)						
	a) Basic	(3.36)	(3.44)	1.17	(6.80)	3.08	0.71
	b) Diluted	(2.97)	(3.05)	1.04	(6.02)	2.73	0.63

**STERLING BIOTECH LIMITED**  
Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

Select Information for the Quarter ended 30 June 2012

**PART II**

Sr. No.	Particulars	Quarter ended 30/06/2012	Previous Quarter ended 31/03/2012	Corresponding Quarter ended 30/06/2011	Six months ended 30/06/2012	Corresponding Six months ended 30/06/2011	Twelve Months ended 31/12/2011
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	- Number of shares	131,861,090	131,861,090	133,666,531	131,861,090	133,666,531	131,861,090
	- Percentage of shareholding	49.23%	49.23%	49.90%	49.23%	49.90%	49.23%
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of shares	50,816,835	50,816,835	27,909,340	50,816,835	27,909,340	50,816,835
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.94%	55.94%	31.35%	55.94%	31.35%	55.94%
	Percentage of shares (as a % of the total share capital of the Company)	18.97%	18.97%	10.42%	18.97%	10.42%	18.97%
	b) Non-encumbered						
	Number of shares	40,023,300	40,023,300	61,125,354	40,023,300	61,125,354	40,023,300
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.06%	44.06%	68.65%	44.06%	68.65%	44.06%
	Percentage of shares (as a % of the total share capital of the Company)	14.94%	14.94%	22.82%	14.94%	22.82%	14.94%

Sr. No.	Particulars	Quarter ended 30/06/2012
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	0

**STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In Lacs)

Sr. No.	Particulars	Six Months Ended 30/06/2012	Twelve Months ended 31/12/2011
		Unaudited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>SHAREHOLDERS' FUND</b>		
	a) Capital	2,678.74	2,678.74
	b) Reserves and Surplus	228,205.61	246,410.14
	c) money received against share warrants	0.00	0.00
	<b>Sub - total Shareholders' Funds</b>	<b>230,884.35</b>	<b>249,088.88</b>
2	Share Application money pending allotment	0.00	0.00
3	Minority Interest	0.00	0.00
4	<b>Non-current liabilities</b>		
	a) Long-term borrowings	122,536.35	150,647.35
	b) Deferred tax liabilities (net)	22,740.01	31,482.01
	c) Other long-term liabilities	0.00	0.00
	d) Long-term provisions	0.00	0.00
	<b>Sub-total - Non-current liabilities</b>	<b>145,276.36</b>	<b>182,129.36</b>
5	<b>Current liabilities</b>		
	a) Short-term borrowings	96,622.48	96,880.26
	b) Trade payables	4,381.89	4,387.89
	c) Other current liabilities	221,652.86	180,162.84
	d) Short-term provisions	218.55	797.65
	<b>Sub-total - Current liabilities</b>	<b>322,875.78</b>	<b>282,228.64</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>699,036.49</b>	<b>713,446.88</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	a) Fixed assets	463,547.76	458,760.50
	b) Goodwill on consolidation	0.00	0.00
	c) Non-current investments	37,650.33	36,500.33
	d) Deferred tax assets (net)	0.00	0.00
	e) Long-term loans and advances	0.00	0.00
	f) Other non-current assets	0.00	0.00
	<b>Sub-total - Non-current assets</b>	<b>501,198.09</b>	<b>495,260.83</b>
2	<b>Current assets</b>		
	a) Current investments	0.00	0.00
	b) Inventories	95,655.74	100,879.12
	c) Trade receivables	70,183.85	72,301.17
	d) Cash and cash equivalents	3,134.83	2,198.72
	e) Short-term loans and advances	28,863.98	42,685.17
	f) Other current assets	0.00	121.87
	<b>Sub-total - Current assets</b>	<b>197,838.40</b>	<b>218,186.05</b>
	<b>TOTAL - ASSETS</b>	<b>699,036.49</b>	<b>713,446.88</b>

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30 JUNE 2012**

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 14 August 2012.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 June 2012
- 4 The Company has Overseas Subsidiary and there are no business operations in the subsidiary company.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 14 August 2012.

**Chetan J. Sandesara  
Joint Managing Director**